RT Journal Article
SR Electronic
T1 Impaired SARS-CoV-2 mRNA vaccine antibody response in chronic medical conditions: a real-world data analysis
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.08.03.21261483
DO 10.1101/2021.08.03.21261483
A1 Liao, Shu-Yi
A1 Gerber, Anthony N.
A1 Zelarney, Pearlanne
A1 Make, Barry
A1 Wechsler, Michael E.
YR 2021
UL http://medrxiv.org/content/early/2021/08/05/2021.08.03.21261483.abstract
AB This study is to investigate whether certain medical conditions may impair antibody response to the mRNA vaccines. In this unique study, participants were drawn from patients in National Jewish Health, a pulmonary specialty outpatient clinic.Our study highlights fact that 26% of our patients (n=226) who had spike protein ab measured at least 14 days post 2nd vaccine had negative spike protein ab testing. We found interstitial lung disease (ILD) to be an independent risk factor for impaired antibody response. While the exact antibody level that confers protection against SARS-CoV-2 is unknown and there may be other non-B cell-mediated protection (e.g. T cell-mediated), our study raises concerns that SARS-CoV-2 vaccination may not result in protective immunity in all populations and may have implications for some as masking and distancing strategies are abandoned.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by funding from the National Jewish Health Department of Medicine and Division of Environmental and Occupational Health Sciences, and Jin Hua Foundation.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the National Jewish Health Institutional Review Board.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesN/A